Skip to main content

Project #23:
Risk of severe COVID-19 outcomes associated with atopic eczema and dupilumab.

  • Type: Research
  • Topic areas: Risk from COVID (short term) [e.g. hospitalisation/death]

In a recent study we found that people with conditions that are related to problems with the immune system, such as Cohn’s disease, psoriasis, and arthritis, and people taking treatments affecting the immune system might be at an increased risk of severe COVID-19 infection. Atopic eczema, a common skin condition presenting with itching and rash, is also thought to be related to problems with the immune system, and some individuals with more severe eczema are treated with dupilumab, a drug that affects the immune system. In this study we aim to explore whether people with eczema and people with eczema who take dupilumab are at an increased risk of severe COVID-19 infection. Clinicians and public health experts need to know this, in order to develop strategies to prevent severe COVID-19 in people with atopic eczema.


  • Study leads: Julian Matthewman
  • Organisation: University of Oxford and London School of Hygiene and Tropical Medicine